Chronic graft-versus-host disease

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Chronic graft-versus-host disease (cGVHD) is the most frequent late complication following allogeneic bone marrow transplantation.
• It represents the primary cause of morbidity and mortality in long-term survivors.
• Despite its impact, cGVHD remains understudied compared to its acute counterpart.

Purpose of the Study:

• To summarize recent advancements in understanding and managing chronic graft-versus-host disease.
• To highlight new diagnostic and staging criteria.
• To discuss emerging therapeutic strategies for steroid-refractory cGVHD.

Main Methods:

• Review of findings from the National Institutes of Health sponsored Chronic Graft-versus-Host Disease Consensus Conference.
• Analysis of emerging research on cGVHD pathophysiology, including the role of B cells.
• Evaluation of novel therapeutic agents and treatment modalities.

Main Results:

• New consensus criteria for diagnosis, staging, pathology, biomarkers, response, and supportive care have been proposed.
• Understanding the pathophysiology, particularly the role of B cells, is influencing treatment approaches.
• Novel agents like pentostatin, mycophenolate mofetil, rituximab, and extracorporeal photochemotherapy show promise.

Conclusions:

• Chronic graft-versus-host disease is a critical area requiring further research and clinical attention.
• Updated diagnostic and staging criteria are essential for consistent patient management.
• Novel therapeutic strategies are improving outcomes for patients with refractory cGVHD, offering new hope for long-term survivors.